Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteVX-803 (M4344, ATR inhibitor 2) is an ATP-competitive, orally active, and selective inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase with Ki of < 150 pM. VX-803 (M4344) potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with IC50 of 8 nM. VX-803 (M4344) exhibits potential antineoplastic activity.
More Information Supplier PageVX-803 (M4344, ATR inhibitor 2) is an ATP-competitive, orally active, and selective inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase with Ki of < 150 pM. VX-803 (M4344) potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with IC50 of 8 nM. VX-803 (M4344) exhibits potential antineoplastic activity.
More Information Supplier PageVX-803 (M4344, ATR inhibitor 2) is an ATP-competitive, orally active, and selective inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase with Ki of < 150 pM. VX-803 (M4344) potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with IC50 of 8 nM. VX-803 (M4344) exhibits potential antineoplastic activity.
More Information Supplier PageVY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
More Information Supplier PageVY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
More Information Supplier PageVY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
More Information Supplier PageVY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
More Information Supplier PageVY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
More Information Supplier PageW-84 dibromide (HDMPPA) is a potent allosteric modulator of M2-acetylcholine receptors, which retards 3HN-methylscopolamine dissociation.
More Information Supplier PageWalnut Leave Extract is extracted from the leaves of Juglans, which has both anti-bacterial and anti-parasitic properties.
More Information Supplier PageWalrycin B is an antibacterial compound and a potent inhibitor of WalR targeting the WalR response regulator.
More Information Supplier PageWaltonitone, an ursane-type pentacyclic triterpene extracted from Gentiana waltonii Burkill, exerts anti-tumor effect.
More Information Supplier PageWax Gourd Peel Extract is extracted from the peel of Benincasa hispida, which is used in the prevention and treatment of metabolic diseases such as hyperlipidemia, hyperglycemia, obesity, and cardiovascular disease.
More Information Supplier PageWax Gourd Seed Extract is extracted from the fruit of Benincasa hispida, which acts as an anti-inflammatory, cardiovascular, hepatoprotective, and exibits cytotoxicity towards breast cancer cells.
More Information Supplier PageWAY-100635 Maleate is a potent and selective 5-HT receptor antagonist with IC50 of 0.95 nM.
More Information Supplier PageWAY-119064 is a potent glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 value of 80.5 nM.
More Information Supplier PageWAY-200070 is a selective estrogen receptor β (ERRβ) agonist with an IC50 of 2.3 nM.
More Information Supplier PageWAY-213613 is a potent, selective nonsubstrate reuptake inhibitor of GLT-1/EAAT2 with IC50 of 85 nM for excitatory amino acid transporter subtype 2 (EAAT2).
More Information Supplier PageWAY-213613 is a potent, selective nonsubstrate reuptake inhibitor of GLT-1/EAAT2 with IC50 of 85 nM for excitatory amino acid transporter subtype 2 (EAAT2).
More Information Supplier PageWAY-262611 (BML-WN110, Compound 5) is a beta-catenin (β-Catenin) agonist that increases bone formation rate with EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also an inhibitor of dickkopf 1 (DKK1).
More Information Supplier PageWAY-262611 (BML-WN110, Compound 5) is a beta-catenin (β-Catenin) agonist that increases bone formation rate with EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also an inhibitor of dickkopf 1 (DKK1).
More Information Supplier PageWAY-262611 (BML-WN110, Compound 5) is a beta-catenin (β-Catenin) agonist that increases bone formation rate with EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also an inhibitor of dickkopf 1 (DKK1).
More Information Supplier PageWAY-297848 is a novel glucokinase activator with potential use as a drug for the prevention or treatment of hyperglycemia, diabetes, obesity, dyslipidemia, metabolic syndrome, etc.
More Information Supplier PageWAY-301398 (6-methoxynaphthalene) can bind to protein kinase C (PKC).
More Information Supplier PageWAY-303290 (GluR6 antagonist-1) is a benzothiophene derivative acting as an ionotropic glutamate receptor 6 (GluR6) antagonist, which can be used for researching acute and chronic neurological disorders.
More Information Supplier PageWAY-316606, a specific antagonist of SFRP1, functions as an activator of canonical Wnt/β-catenin signalling in the human hair bulb.
More Information Supplier PageWAY-316606, a specific antagonist of SFRP1, functions as an activator of canonical Wnt/β-catenin signalling in the human hair bulb.
More Information Supplier PageWAY-316606, a specific antagonist of SFRP1, functions as an activator of canonical Wnt/β-catenin signalling in the human hair bulb.
More Information Supplier PageWAY-316606, a specific antagonist of SFRP1, functions as an activator of canonical Wnt/β-catenin signalling in the human hair bulb.
More Information Supplier PageWAY-340935 (VEGFR2-IN-2) can inhibit the function of VEGFR2 and the anti-proliferative activity against the H460 cell line is produced partly by interaction of VEGFR protein.
More Information Supplier Page
